Back to search

University of Ioannina

Επίδραση των συνδυασμών βαλσαρτάνης/ αμλοδιπίνης ή ντελαπρίλης/μανιδιπίνης ή τελμισαρτάνης/αμλοδιπίνης στην αντίσταση στην ινσουλίνη σε υπερτασικούς ασθενείς με διαταραχή γλυκόζη νηστείας

Abstract

dc:description

Background: The effect of antihypertensive drugs on glucose homeostasis and insulin resistance remains an issue under investigation. There is evidence that renin-angiotensin system (RAS) blockers may favorably affect glucose metabolism, while treatment with calcium channel blockers (CCBs) is considered to have an overall neutral metabolic effect. However, the effects on glycemic indices may differ among agents within the same class of antihypertensive drugs.Objective: To evaluate the effects of different fixed-dose single pill combinations of RAS blockers with CCBs on homeostatic model assessment for insulin resistance (HOMA-IR).Methods: Drug-naive patients with arterial hypertension (AH) and impaired fasting glucose (IFG) were randomly allocated to open-label fixed, single pill combinations of valsartan 160 mg/day plus amlodipine 5 mg/day (VAL/AMLO group, n = 54), delapril 30 mg/day and manidipine 10 mg/day (DEL/MANI group, n = 53) or telmisartan 80 mg/day and amlodipine 5 mg/day (TEL/AMLO group, n = 51) for 12 weeks. Glycemic indices and HOMA-IR were determined at baseline and post-treatment.Results: A total of 158 patients were included. All treatment combinations effectively reduced blood pressure (systolic and diastolic) to similar levels (all p < 0.001). A decrease in the HOMA-IR index by 22.55% (p < 0.01) was noted following treatment with TEL/AMLO, while an increase by 1.4% (p = 0.57) was observed in the VAL/AMLO group and by 12.65% (p = 0.072) in the DEL/MANI group. These changes were significantly different between TEL/AMLO and DEL/MANI (p < 0.05) as well as between TEL/AMLO and VAL/AMLO (p < 0.001). No statistically significant changes were observed in the lipid parameters for each treatment group. Only DEL/MANI treatment resulted in significant reductions in lipid parameters; total cholesterol and triglyceride levels. TEL/AMLO administration resulted in statistically significant reduction in γ-GT levels. Renal function was not adversely affected by any of the 3 treatment groups. TEL/AMLO treatment resulted in greater reductions in urine albumin levels per gram of urine creatinine (uMalb/uCr ratio) than the other groups. No significant changes in electrolyte levels were observed for all treatment groups. Regarding serum potassium levels, there was not observed any incidence of hyperkalemia (> 5 mEq/L) either at baseline visit or at the end of the study follow-up period (DEL/MANI: 4.34 vs 4.36, TEL/AMLO: 4.34 vs 4.48, VAL/AMLO: 4.3 vs 4.42 mEq/L, respectively). The primary goal of antihypertensive treatment (BP < 140/90 mmHg) according to the ESC 2013, 2018 and 2021 guidelines was achieved in approximately half of the patients (50.94%, n = 27) in the DEL/MANI group. In the other 2 treatment groups, less than half of patients (47.06%, n = 24 in the TEL/AMLO group and 37.04%, n = 20 in the VAL/AMLO group) achieved the primary BP goal. In contrast, the rate of achieving the more ambitious BP goal < 130/80 mmHg was even lower for all 3 treatment groups (5.66% for the DEL/MANI group, 5.88% for the TEL/AMLO group and 9.26% for the VAL/AMLO group).Conclusions: Despite similar antihypertensive action, the effect of fixed, single pill combinations with TEL/AMLO, VAL/AMLO and DEL/MANI on insulin resistance is in favor of TEL/AMLO.

Degree

thesis:*
Grantor dc:publisher
University of Ioannina
Year dc:date
2022

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Liontos, Angelos
  • Λιόντος, Άγγελος

Subjects

dc:subject × 16

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/52835

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Liontos, Angelos; Λιόντος, Άγγελος. Επίδραση των συνδυασμών βαλσαρτάνης/ αμλοδιπίνης ή ντελαπρίλης/μανιδιπίνης ή τελμισαρτάνης/αμλοδιπίνης στην αντίσταση στην ινσουλίνη σε υπερτασικούς ασθενείς με διαταραχή γλυκόζη νηστείας. University of Ioannina, 2022. http://hdl.handle.net/10442/hedi/52835